Efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk newly diagnosed multiple myeloma (NDMM) with an inadequate response to frontline autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up Meeting Abstract
| Authors: | Dhodapkar, M. V.; Alsina, M.; Berdeja, J. G.; Patel, K. K.; Richard, S.; Vij, R.; Leleu, X.; Egan, D. N.; Bergsagel, P. L.; Reshef, R.; Usmani, S. Z.; Truppel-Hartmann, A.; Basudhar, D.; Thompson, E.; Zheng, X.; Eliason, L.; Zhong, X.; Greggio, C.; Tran, S.; Chaudhry, M.; Carrasco-Alfonso, M. J.; Siegel, D. S. |
| Abstract Title: | Efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk newly diagnosed multiple myeloma (NDMM) with an inadequate response to frontline autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 2101 |
| Language: | English |
| ACCESSION: | WOS:001159306708074 |
| DOI: | 10.1182/blood-2023-173970 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
